


### **MEDICINAL PRODUCTS 2018**

## **ImmuCell**

## IMMUCELL CORP DE Rank 14 of 49





#### **MEDICINAL PRODUCTS 2018**

### **ImmuCell**

# IMMUCELL CORP DE Rank 14 of 49

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 73% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 37% points.

The company's Economic Capital Ratio, given in the ranking table, is 88%, being 110% points above the market average of -22%.

Input Variable	Value in 1000 USD
Assets, Current	7,507
Assets, Non-Current	0.92
General and Administrative Expense	3,418
Goodwill	248
Liabilities, Current	2,064
Liabilities, Non-Current	8,640
Other Assets	473
Other Compr. Net Income	23
Other Expenses	5,135
Other Liabilities	0
Other Net Income	0
Other Revenues	10,431
Property, Plant and Equipment, Net	26,070
Research and Development	2,047

Output Variable	Value in 1000 USD
Liabilities	10,704
Assets	34,299
Expenses	10,599
Revenues	10,431
Stockholders Equity	23,595
Net Income	-168
Comprehensive Net Income	-157
Economic Capital Ratio	88%

